-
Mashup Score: 2The 10 biggest science stories of 2022 – chosen by scientists - 2 year(s) ago
From moon missions to fast-charging batteries and AI-sourced antibiotics, in no particular order, the year’s significant scientific developments
Source: the GuardianCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 9
The FDA approved the first gene therapy to treat people with hemophilia B, an inherited bleeding disorder. It will cost $3.5 million, making it the most expensive drug approved to date.
Source: STATCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0RISE UP Warrior Partnership Video - 2 year(s) agoSource: YouTubeCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1The world’s platform for change - 3 year(s) ago
Change.org is the world’s largest petition platform, using technology to empower more than 200 million users to create the change they want to see.
Source: Change.orgCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Heardle - That daily musical intros game - 3 year(s) ago
Guess the song from the intro in as few tries as possible.
Source: www.heardle.appCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 3Agios wins FDA approval for drug to treat rare form of anemia - 3 year(s) ago
The FDA has approved a new drug from Agios Pharmaceuticals to treat people with a rare form of anemia.
Source: STATCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1
The Cambridge company’s CEO says it has the potential to become a blockbuster drug.
Source: BostonGlobe.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2Agios wins FDA approval for drug to treat rare form of anemia - 3 year(s) ago
The FDA has approved a new drug from Agios Pharmaceuticals to treat people with a rare form of anemia.
Source: STATCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1Agios' first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder - 3 year(s) ago
More than a decade after its founding, Agios Pharmaceuticals has its first FDA green light. With the approval for Pyrukynd to treat hemolytic anemia in adults with pyruvate kinase deficiency, the company is off and running in the commercial arena.
Source: FiercePharmaCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1
For Sol Schulman,
Source: HemAwareCategories: Hematologists1, Latest HeadlinesTweet
https://t.co/yHZDZAgB1k